Abstract
Abstract: Background: Topotecan monotherapy is an effective treatment in recurrent, metastatic platinum-resistant epithelial ovarian cancer, but this regimen has not been well studied in Vietnam. This study aimed to tackle this problem. Methods: Study of 32 ovarian cancer patients in recurrent or metastatic setting, progressed after platinum-based chemotherapy were treated with Topotecan at Hanoi Oncology Hospital, National Cancer Hospital and Hanoi Medical University Hospital between January 2016 and July 2019. Results: Mean age was 58.6 ± 7 (43 – 72). Most patients had been treated with more than one regimen. 51.3% of all patients gained clinical benefit. Median progresssion free survival was 6.1 months. Median overall survival was 11.8 months. Most toxicities was in grade 1 or 2 with the most common complaint was fatigue. Conclusion: Topotecan is a considerable option in platinum-resistant ovarian cancer with certain clinical benefits. Key words: recurrent, metastatic setting ovarian cancer, platinum resistance, topotecan
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
